$IOVA "Merck defends its dosing for pembrolizumab (Keytruda), saying it’s based on extensive testing and that unstudied changes could compromise effectiveness. A University of Chicago oncologist counters that the profitability of such drugs for hospitals is precisely why no

stocktwits · 2026-08-22 · Bullish AI sentiment

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。